Macedonian Journal of Medical Sciences
[International, Peer Reviewed]

 

About MJMS

Our policies

MJMS Online

For contributors

Services

Why publish in MJMS?
Editors
Boards
Indexing
Membership 

Editorial & publishing policies
Competing interests policy 
Open access
Open access license

Reviewer guidelines

Online first
Current issue
Journal archive

Online first fact sheet
Free Registration

Guidelines  [pdf]
Online submission
Help for authors
Reviewers of MJMS

Contact

Transliteration
Subscriptions

Advertising
Reprints and permissions
Resources

 

Abstract                                                                         [Full-Text PDF] [Macedonian Abstract] [OnlineFirst Full-Text PDF]

 

Macedonian Journal of Medical Sciences. 2008 Sep 15;1(1):50-58.

doi:10.3889/MJMS.1857-5773.2008.0002

Clinical Science

 

Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients

 

Zlate Stojanoski1, Aleksandra Pivkova1, Sonja Genadieva-Stavrik1, Lidija Cevreska1, Milena Petrovska2, Borche Georgievski1

1Hematology Clinic, Medical Faculty, University Stís Cyril and Methodius, Skopje; 2Institute of Microbiology and Parazitology, Medical Faculty, University Stís Cyril and Methodius, Skopje, Republic of Macedonia.

 

Background. According to immunological deficit the period after hematopoietic stem cell transplantation (HSCT) can be divided in three phases: aplastic phase, phase of acute GVHD, and phase of chronic GVHD. Fungal infections are predominant in first, aplastic phase. Deep neutropenia and implantation of central venous catheter are two major risk factors contributing to infection.

Aim. To retrospectively analyze fungal infections, fungal isolates and to compare success of different antifungal strategies during the first 30 days after HSCT.

Material and methods. During a 7 year period (2000-2007), we have performed 128 HSCT in 120 patients with different hematological diseases. Male: 62 Female: 58. Median age: 34 years. Patients were treated in sterile room, conditioned with HEPA filters, and low microbes diet. Antifungal prophylaxis with Fluconazole 200mg, Itraconazole 200mg, or combination Fluconazole200/Itraconazole 200 (in high-risk patients) was administered from day 0 until day +100.

Results. Patients treated with combination of Fluconazole200/Itraconazol200 have had only few oropharyngeal candidiasis, without signs of invasive fungal infection. There is no statistically significant difference between the prophylaxis with Fluconazole and Itraconazole, (p=0,302). Non-Albicans Candida is predominantly isolated funga (Non-Albicans Candida vs. Candida Albicans: 54% vs. 46%). There is no isolation of Aspergillus during the first phase after HSCT in our group of patients.

Concluson. The rising incidence of invasive fungal infections and the currently problematic early diagnosis call for an intensive exploration of new drugs and further developments in diagnosis and treatment of invasive fungal infection.

 

Key words: Fungal infections; stem-cell transplantation.

 


Publication of the MJMS is supported by the Macedonian Ministry of Education and Sciences.
Publisher:
Institute of Immunobiology and Human GeneticsSkopje, Republic of Macedonia.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
MJMS Print (ISSN 1857-5749) is an international peer-reviewed, Open Access journal published four times per year.
MJMS Online (ISSN 1857-5773) offers free access to all articles at http://www.mjms.ukim.edu.mk/.

Creative Commons Attribution LicenseAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution License.